GS
Highly rated in
35
conditions

Dr. Gilles A. Salles

Memorial Hematology Lymphoma Group
New York, NY
Highly rated in
35
conditions
Specialties:Hematology Oncology
Experience:2 Years
Clinical Trials:Currently Recruiting for 6 Trials
Accepts:Medicare
Highly rated in
35
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Gilles A. Salles' experience treating your condition:
About Dr. Gilles A. Salles

Gilles Salles is a Hematologist Oncology expert in New York, New York. Salles has been practicing medicine for over 2 years and is highly rated in 35 conditions, according to our data. His top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant. He is licensed to treat patients in New York.

His clinical research consists of co-authoring 499 peer reviewed articles and participating in 33 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Gilles A. Salles it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
Locations
1275 York Ave, New York, NY 10065
Background & Education
Graduate Institution
Other, 2021
Specialties
Hematology Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
Memorial Sloan Kettering Cancer Center
Shore Medical Center
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

33 Clinical Trials
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Recruiting
Publish Date: December 07, 2022
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
An Exploratory Study to Correlate the Level of Cell-free DNA With Response to First-line Treatment in Patients With Follicular Lymphoma
Enrollment Status: Recruiting
Publish Date: October 04, 2022
Intervention Type: Diagnostic Test, Other
Study Phase: Phase 1
A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP
Enrollment Status: Recruiting
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drugs: TazemetostatRituximabCyclophosphamideVincristineDoxorubicinPrednisolone
Study Phase: Phase 1/Phase 2
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Enrollment Status: Recruiting
Publish Date: April 20, 2022
Intervention Type: Drug
Study Drug: Tinostamustine
Study Phase: Phase 1
A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE
Enrollment Status: Recruiting
Publish Date: July 27, 2021
Intervention Type: Other
The ARCAN Database is Used for Retrospective Non-interventional Research Projects. The Database Collects Clinical and Laboratory Data From Patients With Lymphoid Malignancies. The Database Doesn't Require Biological Sample of Patients, it Records Only Information Based on the Patients' Medical File.
Enrollment Status: Recruiting
Publish Date: March 11, 2019
Intervention Type: Other
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Enrollment Status: Active, not recruiting
Publish Date: November 25, 2022
Intervention Type: Drug, Biological
Study Drugs: Axicabtagene CiloleucelCyclophosphamideFludarabine
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label Study Evaluating Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: October 27, 2022
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene CiloleucelPlatinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in respondersCyclophosphamideFludarabine
Study Phase: Phase 3
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study
Enrollment Status: Completed
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drugs: DoxorubicinBleomycinVinblastineDacarbazineBrentuximab
Study Phase: Phase 2
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drugs: R-CHOPR-CHOP/R-HADRituximabLenalidomide
Study Phase: Phase 3
Phase I Study of Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: August 12, 2022
Intervention Type: Drug
Study Drugs: AbexinostatIbrutinib
Study Phase: Phase 1/Phase 2
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: August 12, 2022
Intervention Type: Drug
Study Drugs: BrentuximabDoxorubicinVinblastineDacarbazine
Study Phase: Phase 2
A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
Enrollment Status: Active, not recruiting
Publish Date: July 29, 2022
Intervention Type: Drug
Study Drug: Parsaclisib
Study Phase: Phase 2
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: July 28, 2022
Intervention Type: Drug, Other
Study Drugs: BrentuximabDacarbazineDoxorubicinVinblastine
Study Phase: Phase 1/Phase 2
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: April 08, 2022
Intervention Type: Drug
Study Drug: Lenalidomide and GA101
Study Phase: Phase 1/Phase 2
A Prospective, Non-interventional, Multinational Study Evaluating the Efficacy and the Safety of High Dose Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation as a Frontline Therapy for Myeloma Patients With Severe Renal Impairment (IRMYG Study)
Enrollment Status: Active, not recruiting
Publish Date: February 08, 2022
Intervention Type: Other
Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
Enrollment Status: Completed
Publish Date: December 07, 2021
Intervention Type: Procedure
Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation
Enrollment Status: Completed
Publish Date: December 07, 2021
Intervention Type: Drug
Study Drugs: BrentuximabEtoposideCarboplatinIfosfamide
Study Phase: Phase 1/Phase 2
Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance
Enrollment Status: Active, not recruiting
Publish Date: September 16, 2021
Intervention Type: Drug
Study Drugs: ObinutuzumabDexamethasoneAracytineCisplatinumEtoposideMelphalanCarmustine
Study Phase: Phase 2
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II Hodgkin's Lymphoma and FDG-PET Positivity After 2 Cycles of ABVD
Enrollment Status: Completed
Publish Date: July 26, 2021
Intervention Type: Drug, Radiation
Study Drugs: BrentuximabCyclophosphamideAdriamycinOncovinBleomycinEtoposideProcarbazinePrednisoneFilgrastim
Study Phase: Phase 2
Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association
Enrollment Status: Completed
Publish Date: April 13, 2021
Intervention Type: Drug
Study Drugs: LenalidomideRituximab
Study Phase: Phase 3
Impact on Quality of Life of an Early Management Supportive Care of Patients With Acute Leukemia in First Relapse.
Enrollment Status: Completed
Publish Date: February 09, 2021
Intervention Type: Other
Study Phase: Not Applicable
Phase Ib - II Study of Entospletinib (ENTO) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients With aaIPI>=1 Treated by Rituximab, Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone (R-CHOP)
Enrollment Status: Terminated
Publish Date: September 02, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation : a Randomized Double Blind Multicenter Prospective Phase III Trial
Enrollment Status: Completed
Publish Date: January 29, 2020
Intervention Type: Device
Study Phase: Phase 3
A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)
Enrollment Status: Terminated
Publish Date: March 13, 2019
Intervention Type: Biological
Study Phase: Phase 2
A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: January 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase Ib Study of Ibrutinib Combined With R-DHAP or R-DHAOx in Patients With B-cell Lymphomas
Enrollment Status: Terminated
Publish Date: October 11, 2018
Intervention Type: Drug
Study Phase: Phase 1
Prospective Multicentre Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® by Intrathecal Injection in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
Enrollment Status: Completed
Publish Date: August 23, 2018
Intervention Type: Drug
Study Phase: Phase 2
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Peripheral Blood Stem Cell Transplantation (ASCT)
Enrollment Status: Unknown status
Publish Date: March 13, 2018
Intervention Type: Drug, Other
Study Drugs: DHAPBrentuximab Vedotin
Study Phase: Phase 1
Advanced Follicular Lymphoma Evaluating the Benefit of Maintenance Therapy With Rituximab (MabThera®) After Induction of Response With Chemotherapy Plus Rituximab in Comparison With no Maintenance Therapy
Enrollment Status: Completed
Publish Date: March 13, 2017
Intervention Type: Drug
Study Phase: Phase 3
Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia, Biomedical Research on Medical Devices Human ImmunTracker and Human Immun'IgH
Enrollment Status: Completed
Publish Date: August 13, 2015
Intervention Type: Biological
FL-2000 Study for Newly Diagnosed Follicular Lymphoma Patients With a High Tumor Burden
Enrollment Status: Completed
Publish Date: July 03, 2007
Intervention Type: Drug
Study Phase: Phase 3
Remission Evaluation Before Intensified Treatment in Lymphoma: Impact of Positron Emission Tomography (PET) Using Fluorine-18-Floro-Deoxyglucose (FDG) in the Therapeutic Prescription. Medico-Economic Randomised Study
Enrollment Status: Unknown status
Publish Date: April 27, 2007
Intervention Type: Procedure
Study Phase: Not Applicable
View 27 Less Clinical Trials -
504 Total Publications
ABCL-088 Subgroup Analysis in RE-MIND2: An Observational, Retrospective Cohort Study of Tafasitamab + Lenalidomide Versus Systemic Therapies in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 27, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
AM
Dr. Alison J. Moskowitz
Hematology Oncology | Hematology | Oncology
Highly rated in
34
conditions
Hematology Oncology
Hematology
Oncology

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 

Alison Moskowitz is a Hematologist Oncology specialist and a Hematologist in New York, New York. Moskowitz has been practicing medicine for over 20 years and is highly rated in 34 conditions, according to our data. Her top areas of expertise are T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. She is licensed to treat patients in New York. Moskowitz is currently accepting new patients.

WT
Dr. William D. Tap
Hematology Oncology
Highly rated in
35
conditions
Hematology Oncology

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 

William Tap is a Hematologist Oncology expert in New York, New York. Tap has been practicing medicine for over 23 years and is highly rated in 35 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Angiosarcoma, Synovial Sarcoma, Tissue Biopsy, and Liver Embolization. He is licensed to treat patients in California and New York. Tap is currently accepting new patients.

RR
Dr. Raajit K. Rampal
Hematology Oncology | Oncology
Highly rated in
47
conditions
Hematology Oncology
Oncology

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 

Raajit Rampal is a Hematologist Oncology specialist and an Oncologist in New York, New York. Rampal has been practicing medicine for over 16 years and is highly rated in 47 conditions, according to our data. His top areas of expertise are Myeloproliferative Neoplasms (MPN), Myelofibrosis, Essential Thrombocythemia, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in New York. Rampal is currently accepting new patients.